Bluebird bio Inc BLUE ticked down slightly in Wednesday's extended session after the development-stage drug company posted a higher-than expected net loss.
The biotechnology company changed hands recently at $95.70, down $0.60.
Bluebird said it can fund operations through 2017 with current cash, cash equivalents and marketable securities.
The company's fourth-quarter net loss of $19.5 million, or $0.67 a share, compared with a year-earlier loss of $8.1 million, or $0.34 a share.
Revenue of $6.3 million for the recent period was unchanged from a year earlier.
Wall Street expected a loss of $0.57 a share, on revenue of $6.18 million.
Bluebird said that during 2015 it will complete enrollment for studies concerning its treatment for childhood cerebral dystrophy, its treatment for beta-thalassemia blood disorder and its treatment for sickle cell disease.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
